Jacada Visual IVR Launched Into Japanese Market by Dimension Data – NTT Neomeit Partnership
Oct 05, 2017 12:00 pm UTC| Business
ATLANTA, Oct. 05, 2017 -- Jacada Ltd. (OTCQB:JCDAF), a leading global provider of customer service technology designed to simplify the interaction between businesses and their customers, announced that Jacada Visual IVR...
Integer Schedules Third Quarter 2017 Earnings Release and Conference Call for October 26, 2017
Oct 05, 2017 12:00 pm UTC| Business
FRISCO, Texas, Oct. 05, 2017 -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for third quarter 2017, after market close on Thursday, October 26,...
Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations
Oct 05, 2017 12:00 pm UTC| Business
WATERTOWN, Mass., Oct. 05, 2017 -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses,...
Oct 05, 2017 12:00 pm UTC| Business
TORONTO, Oct. 05, 2017 -- RioCan Real Estate Investment Trust (“RioCan”) (TSX:REI.UN) is pleased to announce that it has entered into agreements with Sears Canada Inc. (“Sears”), which received court approval on October...
Constellation Brands Reports Second Quarter Fiscal 2018 Results
Oct 05, 2017 11:36 am UTC| Business
VICTOR, N.Y., Oct. 05, 2017 -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, reported today its second quarter fiscal 2018 results. A conference call to discuss the financial...
Gulfport Energy Corporation Launches Proposed $450 Million Offering of Senior Notes
Oct 05, 2017 11:34 am UTC| Business
OKLAHOMA CITY, Oct. 05, 2017 -- Gulfport Energy Corporation (NASDAQ:GPOR) (“Gulfport”) today announced that it proposes to offer, subject to market conditions and other factors, $450 million aggregate principal amount...
Oct 05, 2017 11:30 am UTC| Business
NEW YORK, Oct. 05, 2017 -- TG Therapeutics, Inc. (NASDQ:TGTX), today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of its proprietary fully-human...